Treatment of antipsychotic-related Akathisia revisited: The role of serotonin 2a receptor antagonists

Michael Poyurovsky, Abraham Weizman

Research output: Contribution to journalArticlepeer-review

Abstract

Akathisia remains a prevalent, clinically significant, and therapeutically challenging adverse event associated with antipsychotic treatment. Compelling evidence supports therapeutic efficacy and clinical utility of agents with marked serotonin 2A receptor antagonism, primarily low-dose mirtazapine, as an effective and well-tolerated antiakathisia treatment.

Original languageEnglish
Pages (from-to)711-714
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume35
Issue number6
DOIs
StatePublished - 3 Nov 2015
Externally publishedYes

Keywords

  • antipsychotic-related akathisia
  • low-dose mirtazapine
  • serotonin 2A receptor antagonism

Fingerprint

Dive into the research topics of 'Treatment of antipsychotic-related Akathisia revisited: The role of serotonin 2a receptor antagonists'. Together they form a unique fingerprint.

Cite this